Core Viewpoint - Evonik's Q1 2025 performance exceeded market expectations, with a notable increase in adjusted EBITDA and free cash flow, indicating strong operational efficiency and resilience in a challenging economic environment [1][2]. Financial Performance - Adjusted EBITDA for Q1 2025 reached €560 million, a 7% increase compared to the previous year [1]. - Free cash flow surged by 53% year-on-year to €195 million, surpassing Q1 2024's €127 million [1]. - Sales remained stable at €3.78 billion, with a 2% increase in volume but a 2% decrease in sales prices [1]. - Net income rose to €233 million, significantly up from €156 million in the same period last year [1]. Business Segment Performance - Specialty Additives: Sales increased by 1% to €923 million, driven by volume growth and favorable exchange rates, with adjusted EBITDA rising to €201 million [3]. - Nutrition & Care: This segment saw a 12% sales increase to €1.007 billion, primarily due to higher volumes and compensation from terminated supply contracts, with adjusted EBITDA growing by 35% to €197 million [4]. - Smart Materials: Sales remained nearly unchanged at €1.098 billion, with adjusted EBITDA declining by 7% to €149 million due to lower precious metal prices [4]. Strategic Adjustments - Despite economic uncertainties, Evonik maintained its full-year guidance for adjusted EBITDA between €2 billion and €2.3 billion [2]. - The company is focusing on cost control and structural optimization to mitigate external risks, implementing a new organizational structure to streamline management and reduce departmental layers [2].
赢创,一季度业绩超预期
DT新材料·2025-05-12 15:57